Comparative Pharmacology
Head-to-head clinical analysis: CLOVIQUE versus INTEGRILIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLOVIQUE versus INTEGRILIN.
CLOVIQUE vs INTEGRILIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CLOVIQUE is a monoclonal antibody that binds to and inhibits the activity of interleukin-6 (IL-6), a pro-inflammatory cytokine. By blocking IL-6 from binding to its receptor, it reduces inflammation and immune responses.
Reversible antagonist of the platelet glycoprotein IIb/IIIa receptor, inhibiting platelet aggregation by preventing fibrinogen binding.
10 mg orally once daily.
Acute coronary syndrome: IV bolus of 180 mcg/kg, followed by continuous IV infusion of 2 mcg/kg/min for up to 72 hours. Percutaneous coronary intervention: IV bolus of 180 mcg/kg immediately before PCI, followed by continuous IV infusion of 2 mcg/kg/min for up to 18-24 hours, with a second 180 mcg/kg bolus 10 minutes after the first.
None Documented
None Documented
Terminal half-life of 22-30 hours; allows once-daily dosing with steady-state achieved in 5-7 days
Terminal elimination half-life: ~2.5 hours (2-3 hours) after intravenous administration; clinical context: rapid clearance allows return of platelet function within 4 hours after infusion cessation.
Renal: 65-75% unchanged; biliary/fecal: 20-25% as metabolites
Renal: ~50% as unchanged drug and metabolites, Biliary/fecal: minimal; total clearance approximately 55-58% renal.
Category C
Category C
Antiplatelet Agent
Antiplatelet Agent